Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 3,484 INR
Change Today 0.00 / 0.00%
Volume 0.0
DRRD On Other Exchanges
Symbol
Exchange
New York
Natl India
Mexico
Frankfurt
As of 7:06 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

dr. reddy's laboratories (DRRD) Snapshot

Open
3,511
Previous Close
3,529
Day High
3,571
Day Low
3,470
52 Week High
04/10/15 - 3,809
52 Week Low
05/19/14 - 2,247
Market Cap
593.4B
Average Volume 10 Days
327.7K
EPS TTM
126.52
Shares Outstanding
170.3M
EX-Date
07/11/14
P/E TM
27.5x
Dividend
18.00
Dividend Yield
0.52%
Current Stock Chart for DR. REDDY'S LABORATORIES (DRRD)

Related News

No related news articles were found.

dr. reddy's laboratories (DRRD) Related Businessweek News

No Related Businessweek News Found

dr. reddy's laboratories (DRRD) Details

Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company in India. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment is also engaged in the operation of biologics business. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to biotech and pharmaceutical companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Proprietary Products segment is involved in the discovery and development of new chemical entities and differentiated formulations for subsequent commercialization. Its differentiated formulations portfolio consists of new, synergistic combinations, and technologies that enhance safety and/or efficacy by modifying pharmacokinetics of existing medicines. This segment is also involved in the Company’s specialty pharmaceuticals business, which conducts sales and marketing operations for in-licensed and co-developed dermatology products. The company’s therapeutic categories include gastro-intestinal, cardiovascular, pain management, and oncology. It also operates in North America, Europe, Russia, other countries of the former Soviet Union, and internationally. Dr. Reddy’s Laboratories Limited has strategic partnership with GlaxoSmithKline plc to develop and market products outside India; and collaboration agreement with Merck Serono to develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. The company was founded in 1984 and is headquartered in Hyderabad, India.

18,421 Employees
Last Reported Date: 06/26/14
Founded in 1984

dr. reddy's laboratories (DRRD) Top Compensated Officers

Co-Chairman, Chief Executive Officer, Member ...
Total Annual Compensation: 6.3M
Chairman of The Board, Member of The Manageme...
Total Annual Compensation: 7.7M
Compensation as of Fiscal Year 2014.

dr. reddy's laboratories (DRRD) Key Developments

Taxus Cardium Pharmaceuticals Group Inc. Enters into Binding Term Sheet with Dr. Reddy’S Laboratories Ltd

Taxus Cardium Pharmaceuticals Group Inc. announced that it has entered into a binding term sheet with Dr. Reddy’s Laboratories Ltd. for an exclusive territorial license covering the co-development, marketing and sales of the Generx® [Ad5FGF-4] angiogenic microvascular gene therapy Phase 3 product candidate for patients with refractory angina, and myocardial ischemia due to cardiac microvascular insufficiency (CMI). The agreement initially covers certain territories and international markets, including Russia, the Commonwealth of Independent States (CIS), Venezuela, Vietnam and Myanmar, and provides the right of first refusal for Dr. Reddy’s Laboratories to negotiate additional exclusive license agreements to market and sell the Generx gene therapy product candidate in over 30 other countries in Latin America and the Association of Southeast Asian Nations. Angionetics Inc. is now responsible for the worldwide commercialization of the Generx gene therapy product candidate. Angionetics retains the full Generx commercialization rights for North America, Europe, Japan, China, the Middle East, and Africa. It is planned that Angionetics will advance forward as a company independent from Taxus Cardium and seek to externally finance the Generx U.S.-based FDA-cleared AWARE Phase 3 clinical study, the international ASPIRE Phase 3 clinical development program and additional U.S.-based and international clinical studies for other potential Generx medical indications. As an international co-development partner, Dr. Reddy’s Laboratories will assist with local country patient recruitment and relationship building with key opinion leaders to accelerate the Angionetics’ international Phase 3 ASPIRE clinical study. Positive safety and efficacy findings from the ASPIRE study were announced at the Annual 2014 Biotechnology Industry Organization Conference following completion of a protocol-specified interim data analysis. In addition, Dr. Reddy’s Laboratories will assist with product registrations and regulatory compliance with local country health authorities. The agreement provides economic support that will be used to advance the international Phase 3 clinical study, a cost sharing arrangement for a planned Phase 4 post-marketing clinical study (intended to expand product labeling), and volume-based royalties on net sales. Dr. Reddy’s Laboratories’ Russian-based business unit.

Dr. Reddy’s Laboratories and Promius Pharma, LLC Announce the Filing of Three NDAs With the USFDA

Dr. Reddy's Laboratories and its subsidiary, Promius Pharma, LLC announced the filing of three 505(b)(2) New Drug Applications (NDAs) with the U.S. Food and Drug Administration (US FDA). The three NDAs - DFD-01, DFD-09, and DFN-11, are in support of Dr. Reddy’s Proprietary Products group, focused on developing and commercializing therapies in dermatology and neurology. DFD-01 and DFD-09 are the first dermatology applications submitted to the NDA that have been fully developed leveraging in-house capabilities. DFD-01 is a corticosteroid delivered in a novel non-irritating spray platform, intended for the treatment of patients suffering from psoriasis. DFD-09 is a modified release oral tetracycline intended for the treatment of rosacea. DFN-11 is the first development program filed in support of a newly created vertical, focused on the US neurology market. DFN-11 is a drug-device combination product intended to treat acute migraine episodes in certain patient populations who are inadequately managed with existing treatment regimens. Upon approval, the products will be commercialized by Promius Pharma.

Dr Reddy's Laboratories Enters into an Agreement with Hetero to Market Hepatitis C Drug Sofosbufir 400 mg Tablets

Dr Reddy's Laboratories announced it has entered into an agreement with Hetero to allow the company to distribute and market chronic Hepatitis C drug Sofosbufir 400 mg tablets, manufactured by Hetero, under the brand name Resof in India. Clinical studies have indicated that Sofosbuvir 400 mg in combination with other agents achieved high cure rates while shortening treatment duration to 12 weeks and reducing or completely eliminating the need for Interferon injections, depending on the viral genotype. According to the World health Organization, close to 12 million Indians suffer from chronic Hepatitis C, a disease that can seriously affect the liver, leading to potentially lifethreatening complications, including liver cancer. Earlier this month, two citybased pharma players, Natco Pharma Limited and Hetero, got approval to manufacture and market generic Sofosbuvir tablets 400 mg, from the Drugs Controller General of India. Sofosbuvir is sold globally by Gilead Sciences Inc. under the Sovaldi brand name. Both the Indian companies had announced that they will market generic Sofosbuvir at a price of INR 19,900 for a bottle of 28 tablets.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DRRD:IN 3,484.15 INR 0.00

DRRD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cadila Healthcare Ltd 1,768 INR +7.00
Cipla Ltd/India 637.65 INR -26.30
Croda International PLC 2,978 GBp -29.00
Sigma-Aldrich Corp $139.00 USD +0.03
Symrise AG €57.16 EUR -0.157
View Industry Companies
 

Industry Analysis

DRRD

Industry Average

Valuation DRRD Industry Range
Price/Earnings 27.3x
Price/Sales 4.1x
Price/Book 5.6x
Price/Cash Flow 27.2x
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DR. REDDY'S LABORATORIES, please visit www.drreddys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.